Larson, Rebecca C. http://orcid.org/0000-0003-0174-061X
Kann, Michael C.
Graham, Charlotte http://orcid.org/0000-0001-7874-7305
Mount, Christopher W.
Castano, Ana P.
Lee, Won-Ho
Bouffard, Amanda A.
Takei, Hana N. http://orcid.org/0009-0001-7388-7736
Almazan, Antonio J. http://orcid.org/0009-0003-4947-3968
Scarfó, Irene
Berger, Trisha R.
Schmidts, Andrea
Frigault, Matthew J.
Gallagher, Kathleen M. E.
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA252940, R01CA238268, R01CA249062)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 18 August 2023
Accepted: 9 November 2023
First Online: 18 November 2023
Competing interests
: RCL and MVM are inventors on patents related to this work, held by Massachusetts General Hospital: “Antibodies and Chimeric Antigen Receptors That Target TACI.” US Provisional Application 62/856,998, filed June 4, 2019. US Provisional Application 62/907,930, filed September 30, 2019. US Provisional Application 63/012,735, filed April 20, 2020. WO PCT/US2020/036108, filed June 4, 2020. US Patent Application 17/616,274, filed on December 3, 2021. National applications filed in AU, CA, CN, EP, JP. RCL has served as a consultant for Syncopation Life Sciences (now CARGO Therapeutics) and is now an employee of Link Cell Therapies. MJF receives research funding from Kite and Arcellx. He receives consulting fees from SOBI, Novartis, BMS, Kite/Gilead, Iovance, and JnJ/Legend. MVM and AS are contributors to patents related to APRIL-based CAR T cells: “T cells expressing an APRIL-based chimeric antigen receptor to target BCMA or TACI-expressing plasma cells and also avoid antigen escape from anti-BCMA therapy”, US Provisional 62/444,622, filed Jan 10, 2017. US Provisional Application 62/516,279, filed June 7, 2017. US Provisional Application 62/580,258, filed November 1, 2017. WO PCT/US2018/013221, filed January 10, 2018. US Patent Application 16/476,595, filed July 9, 2019. National applications filed in AU, CA, CN, EP, JP. US Provisional Application 62/629,558, filed February 12, 2018. US Provisional Application 62,771,998, filed November 27, 2019. US Provisional Application 62/773,001, filed November 29, 2018. WO PCT/US2019/013103, filed January 10, 2019. US Patent Application 16/961,189, filed July 9, 2020. MVM is an inventor on additional patents related to adoptive cell therapies held by Massachusetts General Hospital and University of Pennsylvania (some licensed to Novartis). MVM holds equity in 2Seventy Bio, TCR2, Century Therapeutics, Oncternal and NexImmune, and has served as a consultant for multiple companies involved in cell therapies. MVM serves on the Board of Directors of 2Seventy Bio. MVM receives sponsored research support from KitePharma and Novartis. The remaining authors declare no competing interests.